These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2995904)

  • 1. [Evaluation of 17-beta-hydroxysteroid dehydrogenase activity as a marker of the hormone dependence of breast cancers].
    Fournier S; Allali F; Durand JC; Sterkers N; Debertrand P; Diebold N; Martin PM; Kuttenn F; Mauvais-Jarvis P
    Pathol Biol (Paris); 1985 Jun; 33(6):659-64. PubMed ID: 2995904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estradiol 17 beta-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency.
    Fournier S; Brihmat F; Durand JC; Sterkers N; Martin PM; Kuttenn F; Mauvais-Jarvis P
    Cancer Res; 1985 Jun; 45(6):2895-9. PubMed ID: 3857123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactate dehydrogenase in breast carcinoma: correlation with estrogen and progesterone receptors.
    Brentani MM; Nagai MA
    Cancer Detect Prev; 1983; 6(1-2):241-7. PubMed ID: 6883383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
    Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
    Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical importance of determining steroid hormone receptors in endometrial adenocarcinomas].
    Avdeev VI; Kuz'mina ZV; Murav'eva NI; Bassalyk LS; Kozachenko VP
    Vopr Onkol; 1987; 33(6):53-7. PubMed ID: 3617601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels.
    Saez S; Martin PM; Chouvet CD
    Cancer Res; 1978 Oct; 38(10):3468-73. PubMed ID: 688231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
    Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with estrogen receptors-alpha (ER-alpha) and -beta (ER-beta) and progesterone receptor abundance in obese and non obese pre- and post-menopausal women.
    Meza-Muñoz DE; Fajardo ME; Pérez-Luque EL; Malacara JM
    Steroids; 2006 Jun; 71(6):498-503. PubMed ID: 16566954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
    Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
    Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Steroid hormone receptors and survival in breast cancer patients].
    Ivanova OA; Tsyrlina EV; Moiseenko VM; Semiglazov VF
    Vopr Onkol; 1986; 32(6):71-6. PubMed ID: 3727485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.